Your browser doesn't support javascript.
loading
Variability in grading of ductal carcinoma in situ among an international group of pathologists.
van Seijen, Maartje; Józwiak, Katarzyna; Pinder, Sarah E; Hall, Allison; Krishnamurthy, Savitri; Thomas, Jeremy Sj; Collins, Laura C; Bijron, Jonathan; Bart, Joost; Cohen, Danielle; Ng, Wen; Bouybayoune, Ihssane; Stobart, Hilary; Hudecek, Jan; Schaapveld, Michael; Thompson, Alastair; Lips, Esther H; Wesseling, Jelle.
Afiliação
  • van Seijen M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Józwiak K; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Pinder SE; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
  • Hall A; Comprehensive Cancer Centre at Guy's Hospital, School of Cancer & Pharmaceutical Sciences, Kings College London, London, UK.
  • Krishnamurthy S; Department of Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust London, London, UK.
  • Thomas JS; Department of Pathology, Duke University Medical Center, Durham, NC, USA.
  • Collins LC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bijron J; Department of Pathology, Western General Hospital, Edinburgh, UK.
  • Bart J; Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
  • Cohen D; Department of Pathology, Martini Hospital, Groningen, The Netherlands.
  • Ng W; Department of Pathology, Isala Hospital, Zwolle, The Netherlands.
  • Bouybayoune I; Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Stobart H; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Hudecek J; Department of Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust London, London, UK.
  • Schaapveld M; Comprehensive Cancer Centre at Guy's Hospital, School of Cancer & Pharmaceutical Sciences, Kings College London, London, UK.
  • Thompson A; Independent Cancer Patients' Voice, London, UK.
  • Lips EH; Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wesseling J; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
J Pathol Clin Res ; 7(3): 233-242, 2021 05.
Article em En | MEDLINE | ID: mdl-33620141
ABSTRACT
The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due to high interobserver variability and the use of multiple guidelines. The aim of this study was to evaluate interobserver agreement in grading DCIS between Dutch, British, and American pathologists. Haematoxylin and eosin-stained slides of 425 women with primary DCIS were independently reviewed by nine breast pathologists based in the Netherlands, the UK, and the USA. Chance-corrected kappa (κma ) for association between pathologists was calculated based on a generalised linear mixed model using the ordinal package in R. Overall κma for grade of DCIS (low, intermediate, or high) was estimated to be 0.50 (95% confidence interval [CI] 0.44-0.56), indicating a moderate association between pathologists. When the model was adjusted for national guidelines, the association for grade did not change (κma = 0.53; 95% CI 0.48-0.57); subgroup analysis for pathologists using the UK pathology guidelines only had significantly higher association (κma = 0.58; 95% CI 0.56-0.61). To assess if concordance of grading relates to the expression of the oestrogen receptor (ER) and HER2, archived immunohistochemistry was analysed on a subgroup (n = 106). This showed that non-high grade according to the majority opinion was associated with ER positivity and HER2 negativity (100 and 89% of non-high grade cases, respectively). In conclusion, DCIS grade showed only moderate association using whole slide images scored by nine breast pathologists. As therapeutic decisions and inclusion in ongoing clinical trials are guided by DCIS grade, there is a pressing need to reduce interobserver variability in grading. ER and HER2 might be supportive to prevent the accidental and unwanted inclusion of high-grade DCIS in such trials.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante / Patologistas Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans País/Região como assunto: America do norte / Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante / Patologistas Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans País/Região como assunto: America do norte / Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article